Review
Oncology
Carlo Putzu, Stefania Canova, Panagiotis Paliogiannis, Renato Lobrano, Luca Sala, Diego Luigi Cortinovis, Francesca Colonese
Summary: Immunotherapy has significantly improved the outcomes of non-small cell lung cancer (NSCLC) patients, with more than 15% achieving long-term survival. This review aims to discuss the optimal duration of immunotherapy in long survivors to balance treatment efficacy and potential side effects, costs, and disease relapse or progression.
Review
Oncology
Bryan Oronsky, Nacer Abrouk, Scott Caroen, Michelle Lybeck, Xiaoning Guo, Xiaohui Wang, Zhongwen Yu, Tony Reid
Summary: For close to 40 years, small-cell lung cancer (SCLC) has been stagnant with no progress or effective treatments. However, between 2018 and 2021, several new drugs were approved, bringing hope to SCLC patients.
Review
Oncology
Selina K. Wong, Wade T. Iams
Summary: The use of immune checkpoint inhibitors (ICIs) has revolutionized the treatment of small-cell lung cancer (SCLC) by providing significant survival benefit. Current trials are exploring the application of ICIs in the limited-stage setting in combination with chemoradiation or as adjuvant treatment post-chemoradiation. Multiple trials have established the combination of first-line ICIs and chemotherapy as the new standard of care for extensive-stage SCLC.
Article
Oncology
Andrew F. Nyein, Shahla Bari, Stephanie Hogue, Yayi Zhao, Bradley Maller, Sybil Sha, Maria F. Gomez, Dana E. Rollison, Lary A. Robinson
Summary: This study retrospectively evaluated the effects of prior antibiotic or chemotherapy use on the response and survival of non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICI). The study found that patients who received antibiotics or prior chemotherapy had worse overall response rates and overall survival, with the impact of chemotherapy being more significant. Further prospective research is needed to validate these findings.
Review
Biology
Lavinia Gatteschi, Mauro Iannopollo, Alessandro Gonfiotti
Summary: Lung cancer, a common malignant tumor, is often treated with surgical resection in early stages, but the 5-year survival rate remains low. Immune checkpoint inhibitors are being studied as a neoadjuvant treatment option, showing promising results compared to standard chemotherapy in terms of effectiveness and tolerability.
Article
Oncology
Manyi Xu, Yue Hao, Zheng Shi, Zhengbo Song
Summary: Immunotherapy rechallenge may be a viable option for patients with resistance, particularly after acquired resistance.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Review
Oncology
Reem Altaf, Sarmad Sheraz Jadoon, Syed Aun Muhammad, Umair Ilyas, Yongtao Duan
Summary: Lung cancer, responsible for thousands of cancer-related deaths, has long been a challenging disease to treat. However, advancements in understanding the molecular pathways and biology of lung cancer have changed its management. Immunotherapies, which previously failed, are now emerging as a novel and effective therapy for lung cancer. This review article focuses on immune checkpoint inhibitors, specifically CTLA-4 and PDL-1 inhibitors, and critically analyzes studies and clinical trials to determine their potential benefits, risks, and adverse events in treating lung carcinoma.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, General & Internal
Angelo Castello, Sabrina Rossi, Luca Toschi, Egesta Lopci
Summary: The study found that the use of antibiotics is associated with poorer treatment response, PFS, and higher metabolic tumor burden in NSCLC patients treated with immune checkpoint inhibitors.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Oncology
Hui Xie, Xuejun Shi, Guangshun Wang
Summary: Lung cancer treatment is entering an era of precision and individualization, with neoadjuvant immunotherapy being applied to resectable NSCLC patients, providing many benefits and improving long-term survival.
AMERICAN JOURNAL OF CANCER RESEARCH
(2021)
Article
Oncology
Li Pang, Mei Xie, Xidong Ma, Aiben Huang, Jialin Song, Jie Yao, Hui Deng, Duchao Zhang, Xuelei Zang, Fangping Ren, Jie Gao, Chongchong Wu, Yuanyong Wang, Xin Zhang, Xinyu Bao, Lei Pan, Xinying Xue
Summary: This study retrospectively analyzed the clinical and imaging data of 704 patients with non-small cell lung cancer who received immunotherapy, and summarized the clinical characteristics and therapeutic effects of checkpoint inhibitor-related pneumonitis.
Review
Oncology
Xingyu Liu, Huifang Xing, Baoxing Liu
Summary: The combination of immune checkpoint inhibitors (ICIs) with chemotherapy has become the new standard first-line treatment for extensive stage small-cell lung cancer (ES-SCLC). Future research should focus on exploring SCLC biology and identifying novel predictive biomarkers in response to ICIs.
AMERICAN JOURNAL OF CANCER RESEARCH
(2022)
Review
Oncology
Claudio Martin, Diego Enrico
Summary: During the past decade, immunotherapy has greatly improved outcomes for NSCLC patients. However, monotherapy with immune checkpoint inhibitors (ICIs) is not effective for all patients, leading researchers to explore combination approaches to optimize clinical outcomes.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Jennifer W. Carlisle, Ticiana Leal
Summary: Small cell lung cancer (SCLC) is a rapidly progressive neuroendocrine carcinoma that has limited effective treatments. Advances in DNA sequencing and whole transcriptomics have identified key subtypes, leading to the development of chemoimmunotherapy as the standard of care for advanced disease. Ongoing research is focused on incorporating immunotherapy into limited stage settings and exploring combination strategies with radiation.
Review
Oncology
Asa P. Y. Lau, Sharon S. Khavkine Binstock, Kelsie L. Thu
Summary: CD47 is a promising immunotherapeutic target in lung cancer, and this review summarizes its roles in tumor biology, its therapeutic potential in non-small cell lung cancer, and the challenges that need to be overcome.
Review
Oncology
Shuang Zhang, Ying Cheng
Summary: Small-cell lung cancer (SCLC) is a deadly type of lung cancer with limited treatment options. Recent studies have shown that adding immunotherapy to chemotherapy can improve the survival of patients with extensive-stage SCLC, establishing a new standard of first-line treatment. This article reviews the current status of first-line immunotherapy, strategies to enhance its efficacy, and the identification of potential predictive biomarkers for immunotherapy in SCLC.
FRONTIERS IN ONCOLOGY
(2023)